The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
He hasn’t delivered what he said he would. My last hopes are FDA partner news or some big contract win and NICE recommendation.
I am in disbelief at the current price. I expected it to be over 50p now.
Roger65 posts exactly like starres these days.
Roger65 sold out by the look of his comment. I reckon now we will surge to 36p.
My last hope is that Genedrive usually surges to at least 30’s in March. If it does again, I am out for good.
You do what you have to do. Don't be influenced by anyone here. My last hope is James Cheek.
Genedrive to surge to 42p hopefully this month.
RUA is the worst company of the lot and way overvalued.
I was expected NICE news and FDA news last month.
I wonder if HE1 does an OBD , GDR and RUA as in crash back down to lows or all time low. Sadly it seems stocks rise and then crash back down.
Https://www.linkedin.com/posts/johnhmcdermott_pharmacogenomics-isnt-special-that-ugcPost-7171946012096319488-UqRG?utm_source=share&utm_medium=member_ios
James Cheek liked this post.
I was thinking we could hit over £1 last year after that. :(
The Company estimates that the total addressable UK market is up to £8.5 million per annum which is based on approximately 100,000 NICU admissions per annum and an estimated customer price per test of more than £80. The EU market is potentially another c. £46.8 million per annum, the U.S. market is c. £34 million and Rest of World markets around £13.8 million. Market estimates are based on end user pricing. The Directors believe that the UK and Europe presents an attractive market opportunity for the Company to target. The Company expects to pursue a distributor model alongside some investment in its own business development activities including an expanded commercial sales and marketing team to help drive initial adoption. A geographic expansion process is underway with targeted launch (outside the UK) expected in Spain, Saudi Arabia, Austria, France and Greece in H1 2023 with other countries to follow. Distributors have already been appointed in 8 countries. The Company is developing materials and undergoing activities to educate the market and drive product awareness.
Genedrive® CYP2C19-ID Kit ("CYP2C19")
The CYP2C19 ID Kit being developed will be used in conjunction with the Genedrive® System to provide a rapid, automated result of targeted CYP2C19 genotypes to inform clinicians on metaboliser status ahead of treatment strategies using drugs that are metabolised by Cytochrome P450 2C19 (CYP2C19). One example of the clinical utility of CYP2C19 metaboliser status in an urgent care setting would be rapid genotyping for the prescription of the anti-platelet therapy, clopidogrel. Clopidogrel is a pro-drug administered for the management of ischaemic strokes and requires conversion to an active form by the enzyme, CYP2C19. The combination of inherited CYP2C19 alleles determines the individual's metaboliser status. The CYP2C19 Kit screens for patients that should metabolize clopidogrel appropriately. Alternative drugs can be given to those that don't respond. CYP2C19 testing could generate more quality adjusted life-years for patients and lower costs compared with no testing.
The Company estimates that the total addressable UK market is up to £8.5 million per annum which is based on approximately 85,000 ischaemic strokes per annum. The EU market is potentially another c. £93.5 million per annum (c. 800,000 strokes per annum), the U.S. market is c. £67.6 million per annum (c. 700,000 strokes per annum) and rest of world markets c. £51.0 million per annum. The Company anticipates the customer price to be approximately £100 per test. The U.S. market has established reimbursement under Medicare (c. US$291). Market estimates are based on estimated end user pricing. NICE has included Genedrive's ® CYP2C19-ID Kit in a new Diagnostics Assessment Programme reviewing general applicability of CYP2C19 testing by any technique. The Company anticipates it could recommend genotyping is appropriate and cost effective.
Surely it deserved to end blue today after so many buys?
Https://shtg.scot/our-advice/clopidogrel-genotype-testing-after-ischaemic-stroke-or-transient-ischaemic-attack-tia/
Surely the Pdf implies news due in March.
March usually a good month for GDR. Last year it peaked at 48.86p to buy which is over 10x the current price. Surely now we progressed a lot more we should at least hit 30’s.
Roger65 still invested in HE1? If not, might as well jump back into Genedrive just as it starts surging to over 50p.🚀
Amazing we are in March and still no final guidance.
If you look at the trades since last Friday, you would think we would be at least around the 6p mark.